Global experience and progress in GreenLight-XPS 180-Watt photoselective vaporization of the prostate.
BPH
GL-XPS
Global Greenlight Group
Global experience
Greenlight
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
21
11
2021
accepted:
18
03
2022
pubmed:
3
5
2022
medline:
9
6
2022
entrez:
2
5
2022
Statut:
ppublish
Résumé
To evaluate changes in global perioperative data of GreenLight-XPS 180-Watt photo-selective vaporization of the prostate (GL-XPS) of the Global Greenlight Group (GGG) database. 3441 men, who underwent GL-XPS for symptomatic BPH between 2011 and 2019 at seven high volume international centers, were included. Primary outcome measurements were operative time (OT; min), effective laser time (LT; min of OT), as well as intraoperative and postoperative adverse events (AEs), all analyzed by year of surgery (2011-2019) and prostate volume (PV) group (< 80 ml vs. 80-150 ml vs. > 150 ml). The median age was 70 years (interquartile range 64-77), the median PV was 64 ml (IQR 47-90). The OT and LT slightly increased but stayed highly efficient all in all. Median OT was 60 min (IQR 45-83) and LT was 33 min (IQR 23-46). Median energy use was 253 kJ (IQR 170-375) with an energy density of 3.94 kJ/ml (IQR 2.94-5.02). The relative probability of perioperative AEs decreased by 17% each year (p < 0.001). The relative probability of perioperative transfusion dropped significantly from 2% in 2011 to 0% in 2019 (p = 0.007). The early postoperative complications (within 30 days after surgery) decreased significantly from 48.8% (n = 106) in 2011 to 24.7% (n = 20) in 2019 (p > 0.001). These findings from the GGG demonstrate significant improvement secondary to growing experience with GL-XPS between 2011 and 2019 in intraoperative AEs, including transfusions, and postoperative AEs. While staying highly efficient in OT and LT of GL-XPS within a 9-year period of experience.
Identifiants
pubmed: 35499590
doi: 10.1007/s00345-022-03997-2
pii: 10.1007/s00345-022-03997-2
pmc: PMC9166849
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1513-1522Informations de copyright
© 2022. The Author(s).
Références
Foster HE, Barry MJ, Dahm P et al (2018) Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline. J Urol 200(3):612–619. https://www.ncbi.nlm.nih.gov/pubmed/29775639
Gratzke C, Bachmann A, Descazeaud A et al (2015) EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 67(6):1099–1109
doi: 10.1016/j.eururo.2014.12.038
Valdivieso R, Hueber PA, Meskawi M et al (2018) Multicentre international experience of 532-nm laser photoselective vaporization with GreenLight XPS in men with very large prostates. BJU Int 122(5):873–878. https://www.ncbi.nlm.nih.gov/pubmed/29570929
Stone BV, Chughtai B, Forde JC et al (2016) Safety and Efficacy of GreenLight XPS laser vapoenucleation in prostates measuring over 150 mL. J Endourol 30(8):906–912. https://www.ncbi.nlm.nih.gov/pubmed/27203515
Nickel JC, Aaron L, Barkin J et al (2018) Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH): 2018 update. Can Urol Assoc J 12(10):303–312. https://www.ncbi.nlm.nih.gov/pubmed/30332601
Bachmann A, Tubaro A, Barber N et al (2014) 180-W XPS GreenLight laser vaporisation versus transurethral resection of the prostate for the treatment of benign prostatic obstruction: 6-month safety and efficacy results of a European Multicentre Randomised Trial–the GOLIATH study. Eur Urol 65(5):931–942
doi: 10.1016/j.eururo.2013.10.040
Reimann M, Fishman N, Almedom Z et al (2018) Perioperative changes and progress in photoselective vaporization of the prostate with GreenLight XPS 180 W system: a single center experience. Urol Int 100(4):463–469. https://www.ncbi.nlm.nih.gov/pubmed/29621785
Law KW, Tholomier C, Nguyen DD et al (2021) Global Greenlight Group: largest international Greenlight experience for benign prostatic hyperplasia to assess efficacy and safety. World J Urol https://www.ncbi.nlm.nih.gov/pubmed/33837819
Parsons JK, Dahm P, Kohler TS et al (2020) Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline amendment 2020. J Urol 204(4):799–804. https://www.ncbi.nlm.nih.gov/pubmed/32698710
Campobasso D, Marchioni M, Altieri V et al (2020) GreenLight photoselective vaporization of the prostate: one laser for different prostate sizes. J Endourol 34(1):54–62. https://www.ncbi.nlm.nih.gov/pubmed/31617419
Gu X, Strom K, Spaliviero M et al (2013) Does prostate configuration affect the efficacy and safety of GreenLight HPS laser photoselective vaporization prostatectomy (PVP)? Lasers Med Sci 28(2):473–478. https://www.ncbi.nlm.nih.gov/pubmed/22460737
Nguyen DD, Misrai V, Bach T et al (2020) Operative time comparison of aquablation, greenlight PVP, ThuLEP, GreenLEP, and HoLEP. World J Urol 38(12):3227–3233. https://www.ncbi.nlm.nih.gov/pubmed/32124018
Valdivieso R, Meyer CP, Hueber PA et al (2016) Assessment of energy density usage during 180W lithium triborate laser photoselective vaporization of the prostate for benign prostatic hyperplasia. Is there an optimum amount of kilo-Joules per gram of prostate? BJU Int 118(4):633–640. https://www.ncbi.nlm.nih.gov/pubmed/26970202
Nguyen DD, Sadri I, Law K et al (2021) Impact of the presence of a median lobe on functional outcomes of greenlight photovaporization of the prostate (PVP): an analysis of the Global Greenlight Group (GGG) Database. World J Urol https://www.ncbi.nlm.nih.gov/pubmed/33388918
Meskawi M, Hueber PA, Valdivieso R et al (2019) Complications and functional outcomes of high-risk patient with cardiovascular disease on antithrombotic medication treated with the 532-nm-laser photo-vaporization Greenlight XPS-180 W for benign prostate hyperplasia. World J Urol 37(8):1671–1678. https://www.ncbi.nlm.nih.gov/pubmed/30478499
Meskawi M, Hueber PA, Valdivieso R et al (2017) Multicenter international experience of 532 nm-laser photo-vaporization with Greenlight XPS in men with large prostates (prostate volume > 100 cc). World J Urol 35(10):1603–1609. https://www.ncbi.nlm.nih.gov/pubmed/28229211
Thomas JA, Tubaro A, Barber N et al (2016) A Multicenter Randomized Noninferiority Trial Comparing GreenLight-XPS Laser Vaporization of the Prostate and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: Two-yr Outcomes of the GOLIATH Study. Eur Urol 69(1):94–102. https://www.ncbi.nlm.nih.gov/pubmed/26283011
Reale G, Marchioni M, Altieri V et al (2020) Operative profile, safety and functional outcomes after GreenLight laser prostate surgery: results from a 12 months follow-up multicenter Italian cohort analyses. Minerva Urol Nefrol 72(5):622–628. https://www.ncbi.nlm.nih.gov/pubmed/32284526
Goueli R, Meskawi M, Thomas D et al (2017) Efficacy, Safety, and Durability of 532 nm Laser Photovaporization of the Prostate with GreenLight 180 W XPS in Men with Acute Urinary Retention. J Endourol 31(11):1189–1194. https://www.ncbi.nlm.nih.gov/pubmed/28844169